Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis

Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Eric L., Smyth, Susan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817733/
https://www.ncbi.nlm.nih.gov/pubmed/24276376
http://dx.doi.org/10.3390/ph6080915
_version_ 1782478119459880960
author Wallace, Eric L.
Smyth, Susan S.
author_facet Wallace, Eric L.
Smyth, Susan S.
author_sort Wallace, Eric L.
collection PubMed
description Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.
format Online
Article
Text
id pubmed-3817733
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38177332013-11-14 Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis Wallace, Eric L. Smyth, Susan S. Pharmaceuticals (Basel) Review Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use. MDPI 2013-08-02 /pmc/articles/PMC3817733/ /pubmed/24276376 http://dx.doi.org/10.3390/ph6080915 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Wallace, Eric L.
Smyth, Susan S.
Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
title Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
title_full Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
title_fullStr Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
title_full_unstemmed Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
title_short Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
title_sort targeting platelet thrombin receptor signaling to prevent thrombosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817733/
https://www.ncbi.nlm.nih.gov/pubmed/24276376
http://dx.doi.org/10.3390/ph6080915
work_keys_str_mv AT wallaceericl targetingplateletthrombinreceptorsignalingtopreventthrombosis
AT smythsusans targetingplateletthrombinreceptorsignalingtopreventthrombosis

Ejemplares similares